Citigroup Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its price objective cut by equities research analysts at Citigroup from $11.00 to $9.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “sell” rating on the life sciences company’s stock. Citigroup’s target price indicates a potential downside of 1.85% from the stock’s previous close.

Several other brokerages have also recently weighed in on IART. Wells Fargo & Company decreased their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Friday, February 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $14.40.

Integra LifeSciences Stock Performance

Integra LifeSciences stock opened at $9.17 on Wednesday. The firm has a market capitalization of $714.71 million, a P/E ratio of -1.36 and a beta of 1.02. The stock has a fifty day moving average price of $11.47 and a two-hundred day moving average price of $12.93. Integra LifeSciences has a 52-week low of $8.91 and a 52-week high of $23.27. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company had revenue of $434.93 million for the quarter, compared to the consensus estimate of $429.62 million. During the same quarter in the previous year, the company earned $0.97 EPS. The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences in the fourth quarter worth about $25,000. GAMMA Investing LLC grew its stake in shares of Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 913 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares in the last quarter. EMC Capital Management acquired a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $75,000. Finally, Tower Research Capital LLC TRC raised its position in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.